BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 2, 2026
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 27, 2007
View Archived Issues
Some Blunt Talk About Money Highlights Kickoff of EuroBIO
Read More
Keryx, Japan Tobacco Deal: Possible $100M For Zerenex
Read More
Partnering Tables Turn As Big Pharma Pitches Biotech
Read More
Alemtuzumab In Phase III Testing Against Rebif In MS
Read More
GlobeImmune Is Advancing Tarmogen With $41M Series C
Read More
Amgen Cutbacks Hit Home As ECCO Data Tumble Forth
Read More
CollaGenex Drops Rosacea Drug After Phase II Failure
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Emergent Snags $448M Deal for Anthrax Vaccine
Emergent BioSolutions Inc. said Wednesday that it signed a three-year contract with the federal government worth up to $448 million to supply anthrax vaccine for the nation's biodefense stockpile. (BioWorld Today)
Read More
NPS, Nycomed Enter Potential $185M Deal Covering Gattex
Read More
